ACP-104 in Acutely Psychotic Subjects With Schizophrenia
Primary Purpose
Schizophrenia
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
ACP-104
ACP-104
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Schizophrenia focused on measuring Schizophrenia, psychotic disorders
Eligibility Criteria
Inclusion Criteria:
- Male or female; 18-60 years of age
- The subject is physically healthy and medically stable.
- The subject is able to provide informed consent
- The subject has been diagnosed with schizophrenia for at least 1 year
- Currently experiencing an acute episode of psychosis
- The subject is willing to comply with all study-related events including in-patient hospitalization for at least 3 weeks.
- The subject has a caregiver who is willing and able to support the subject to ensure compliance with treatment and outpatient visits.
- If the subject is female, subject must be of non-childbearing potential - OR- if she is capable of becoming pregnant, agrees to commit to use one of the approved methods of contraception, as defined by the protocol.
Exclusion Criteria:
- If the subject is a pregnant or lactating (breast-feeding) female.
- The subject has a significant risk of suicide, homicide, and/or harm to self or others.
- Subject's psychotic symptoms have not improved with a therapeutic dose of antipsychotic treatment over the last 2 years.
- The subject is experiencing his/her first episode of schizophrenia.
- The subject has another psychotic disorder or has a history of autistic disorder or other pervasive developmental disorder (for example, mental retardation).
- The subject has been prescribed or exposed to clozapine before.
- The subject has donated blood or plasma within 56 days prior to the Screening Visit.
- The subject has participated in any clinical study within 30 days prior to the Screening Visit.
In addition to the criteria described above, subjects will be evaluated at screening to ensure that all criteria for study participation are met. These evaluations will include specific measures of the subject's health, including psychosis (mental health -the extent to which subject is unable to think clearly), heart condition, and pregnancy status. Patients may be excluded from the study based on these assessments (and specifically if it is determined that their baseline condition does not meet all protocol-specified entry criteria).
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Placebo Comparator
Arm Label
1
2
3
Arm Description
Outcomes
Primary Outcome Measures
PANSS
Secondary Outcome Measures
Full Information
NCT ID
NCT00490516
First Posted
June 21, 2007
Last Updated
April 18, 2017
Sponsor
ACADIA Pharmaceuticals Inc.
1. Study Identification
Unique Protocol Identification Number
NCT00490516
Brief Title
ACP-104 in Acutely Psychotic Subjects With Schizophrenia
Official Title
A Six-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase II Study of the Efficacy and Safety of ACP-104 in Acutely Psychotic Subjects With Schizophrenia
Study Type
Interventional
2. Study Status
Record Verification Date
April 2017
Overall Recruitment Status
Completed
Study Start Date
June 2007 (undefined)
Primary Completion Date
February 2008 (Actual)
Study Completion Date
February 2008 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
ACADIA Pharmaceuticals Inc.
4. Oversight
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a randomized, double-blind, placebo-controlled parallel-group, 6-week study, evaluating two dose levels of ACP-104 or Placebo twice a day in patients with schizophrenia who are experiencing an acute psychotic episode.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Schizophrenia
Keywords
Schizophrenia, psychotic disorders
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
247 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Title
2
Arm Type
Experimental
Arm Title
3
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
ACP-104
Intervention Description
200 mg, tablet, BID, 6 weeks
Intervention Type
Drug
Intervention Name(s)
ACP-104
Intervention Description
100 mg, tablet, BID, 6 weeks
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
placebo, tablet BID, 6 weeks
Primary Outcome Measure Information:
Title
PANSS
Time Frame
6 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or female; 18-60 years of age
The subject is physically healthy and medically stable.
The subject is able to provide informed consent
The subject has been diagnosed with schizophrenia for at least 1 year
Currently experiencing an acute episode of psychosis
The subject is willing to comply with all study-related events including in-patient hospitalization for at least 3 weeks.
The subject has a caregiver who is willing and able to support the subject to ensure compliance with treatment and outpatient visits.
If the subject is female, subject must be of non-childbearing potential - OR- if she is capable of becoming pregnant, agrees to commit to use one of the approved methods of contraception, as defined by the protocol.
Exclusion Criteria:
If the subject is a pregnant or lactating (breast-feeding) female.
The subject has a significant risk of suicide, homicide, and/or harm to self or others.
Subject's psychotic symptoms have not improved with a therapeutic dose of antipsychotic treatment over the last 2 years.
The subject is experiencing his/her first episode of schizophrenia.
The subject has another psychotic disorder or has a history of autistic disorder or other pervasive developmental disorder (for example, mental retardation).
The subject has been prescribed or exposed to clozapine before.
The subject has donated blood or plasma within 56 days prior to the Screening Visit.
The subject has participated in any clinical study within 30 days prior to the Screening Visit.
In addition to the criteria described above, subjects will be evaluated at screening to ensure that all criteria for study participation are met. These evaluations will include specific measures of the subject's health, including psychosis (mental health -the extent to which subject is unable to think clearly), heart condition, and pregnancy status. Patients may be excluded from the study based on these assessments (and specifically if it is determined that their baseline condition does not meet all protocol-specified entry criteria).
Facility Information:
City
Anaheim
State/Province
California
ZIP/Postal Code
92805
Country
United States
City
Costa Mesa
State/Province
California
ZIP/Postal Code
92626
Country
United States
City
Covina
State/Province
California
ZIP/Postal Code
91724
Country
United States
City
Culver City
State/Province
California
ZIP/Postal Code
90232
Country
United States
City
Garden Grove
State/Province
California
ZIP/Postal Code
92845
Country
United States
City
Glendale
State/Province
California
ZIP/Postal Code
91206
Country
United States
City
Huntington Beach
State/Province
California
ZIP/Postal Code
92647
Country
United States
City
Oceanside
State/Province
California
ZIP/Postal Code
92056
Country
United States
City
Paramount
State/Province
California
ZIP/Postal Code
90723
Country
United States
City
Pasadena
State/Province
California
ZIP/Postal Code
91107
Country
United States
City
Pico Rivera
State/Province
California
ZIP/Postal Code
90660
Country
United States
City
Riverside
State/Province
California
ZIP/Postal Code
92506
Country
United States
City
San Diego
State/Province
California
ZIP/Postal Code
92108
Country
United States
City
Bradenton
State/Province
Florida
ZIP/Postal Code
34208
Country
United States
City
Kissimmee
State/Province
Florida
ZIP/Postal Code
34741
Country
United States
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30308
Country
United States
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21202
Country
United States
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63118
Country
United States
City
Willingboro
State/Province
New Jersey
ZIP/Postal Code
08046
Country
United States
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19139
Country
United States
City
Austin
State/Province
Texas
ZIP/Postal Code
78754
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
ACP-104 in Acutely Psychotic Subjects With Schizophrenia
We'll reach out to this number within 24 hrs